Intec Pharma Ltd. (NASDAQ:NTEC) and Zai Lab Limited (NASDAQ:ZLAB) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.
Valuation and Earnings
In table 1 we can see Intec Pharma Ltd. and Zai Lab Limited’s top-line revenue, earnings per share and valuation.
Table 2 demonstrates the net margins, return on assets and return on equity of Intec Pharma Ltd. and Zai Lab Limited.
Institutional and Insider Ownership
Intec Pharma Ltd. and Zai Lab Limited has shares owned by institutional investors as follows: 39.64% and 68.9%. 11.81% are Intec Pharma Ltd.’s share owned by insiders. Comparatively, insiders own roughly 35.54% of Zai Lab Limited’s shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and